Aspire Biopharma Holdings, Inc. Files Amended 10-K/A: What Investors Need to Know

Key Highlights

• Amended Filing: Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP, ASBPW) has submitted an Amendment No. 1 (10-K/A) to its Annual Report for the fiscal year ended December 31, 2025.
• Reason for Amendment: The amendment was filed specifically to include the Report of Independent Registered Public Accounting Firm (Bush & Associates CPA LLC) for the year ended December 31, 2024, which was inadvertently omitted in the original filing on March 30, 2026.
• No Other Changes: The amendment does not include any modifications or updates to the other disclosures, financial statements, or business information contained in the original filing. It is solely to add the omitted auditor’s report.
• New Certifications: The filing includes new certifications from the principal executive officer and principal financial officer, as well as an updated auditor consent.
• Reverse Stock Split: All share numbers in the report reflect the 1-for-40 reverse stock split that was effected on January 16, 2026, a notable event for assessing share capital and valuation.

Details Investors Should Be Aware Of

• Trading Information: Aspire Biopharma Holdings, Inc. is listed on Nasdaq under the ticker symbols ASBP (common stock) and ASBPW (warrants). The company’s common stock has a par value of \$0.0001 per share, and the warrants are exercisable for one share of common stock each.
• Company Status:
  • Not a well-known seasoned issuer.
  • Non-accelerated filer and smaller reporting company.
  • Not an emerging growth company and not a voluntary filer.
  • Filed all required reports and Interactive Data Files timely.
• No Error Corrections or Restatements: The financial statements in this amendment do not reflect any corrections or restatements of previously issued financial statements.
• No Documents Incorporated by Reference: The amendment specifies that no other documents are incorporated by reference.
• Business Overview: The company’s business, risk factors, unresolved staff comments, properties, legal proceedings, and other required disclosures are unchanged from the original 10-K filing.

Potential Impact and Price Sensitive Information

Shareholders and investors should note:

• The inclusion of the auditor’s report is a requirement for compliance but does not represent new financial information, errors, or restatements. This means there is no direct impact on the company’s financial condition, business outlook, or risk profile as previously disclosed.
• The confirmation of the 1-for-40 reverse stock split is highly relevant for valuation, trading, and share counts. Investors should recalculate any historical per-share values or holdings accordingly.
• The company remains listed on Nasdaq and is in compliance with reporting requirements, which may be interpreted as a positive for governance and transparency.
• No new material risks, legal proceedings, or changes to business strategy have been disclosed in this amendment.

Forward-Looking Statements

The company’s report includes a standard caution regarding forward-looking statements, emphasizing that actual results may differ from expectations due to various risk factors, including the ability to complete business combinations, retain key personnel, and other uncertainties affecting the company and its industry.

Summary Table of Contents

The amendment provides a full table of contents, covering business, risk factors, management’s discussion and analysis, financial statements, controls and procedures, executive compensation, related party transactions, and more. No sections other than the auditor’s report and officer certifications have been updated.

Conclusion

Bottom Line for Investors:

The amended 10-K/A is a compliance-focused update to include an omitted auditor report for 2024. There are no new financial results, risks, or business outlook changes in this amendment. The most notable price-sensitive event remains the previously effected 1-for-40 reverse stock split. Investors should continue to monitor for future filings that may contain substantive business or financial updates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings and consult with their financial advisors before making any investment decisions. The author and publisher accept no liability for reliance on the information presented.

View Aspire Biopharma Holdings, Inc. Historical chart here